• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

    7.170 -0.280 (-3.76%)
    Streaming Delayed Price Updated: 12:07 PM EDT, May 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ocular Therapeutix, Inc. - Common Stock

    < Previous 1 2 Next >
    R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
    EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
    From Ocular Therapeutix, Inc.
    Via Business Wire
    AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
    From Ocular Therapeutix, Inc.
    Via Business Wire
    Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
    From Ocular Therapeutix
    Via Business Wire
    Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
    From Ocular Therapeutix, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.